We present the Evolutionary Map of the Universe (EMU) survey conducted with the Australian Square Kilometre Array Pathfinder (ASKAP). EMU aims to deliver the touchstone radio atlas of the southern hemisphere. We introduce EMU and review its science drivers and key science goals, updated and tailored to the current ASKAP five-year survey plan. The development of the survey strategy and planned sky coverage is presented, along with the operational aspects of the survey and associated data analysis, together with a selection of diagnostics demonstrating the imaging quality and data characteristics. We give a general description of the value-added data pipeline and data products before concluding with a discussion of links to other surveys and projects and an outline of EMU’s legacy value.

Neuropsychological disorders, including anxiety, depression, and dementia, are significant public health problems among older adults. While psychotropics are effective treatments, long-term treatment often has adverse side effects(1). Many patients often seek healthy food consumption as an alternative preventive strategy. Dietary fibre has been suggested for many health benefits, including cardiometabolic health and anti-inflammation, which may influence neurological health through the gut-brain axis(2). However, fibre’s role in neuropsychological health outcomes in older people is unclear. This study examined the potential role of dietary fibre intake and consumption of fibre-rich foods in neurological health outcomes in older Australians. We utilised data from the Ageing Study (MAS) of 1,037 participants aged 70–90(3). At baseline, dietary fibre, whole grains, fresh fruit, vegetables, and nuts and legumes consumption was estimated using the Cancer Council of Victoria food frequency questionnaire. The intake amount was further derived into tertiles (T), with T1 in the lower 33rd%tile and T3 in the upper 33rd%tile. Depressive symptoms (Geriatric Depression Scale), anxiety symptoms (Goldberg Anxiety Scale), and psychological distress (Kessler Psychological Distress Scale) were assessed. Linear regression models were used to estimate beta coefficients for the associations cross-sectionally. Incident dementia was defined using diagnostic criteria, clinical assessments, and a consensus panel review. Nine hundred and sixty-three participants were followed up from the baseline (2005) until wave 4 (2011) [median: 5.8 (IQR: 3.1–5.9) years; 97 incident cases). Incident depression was defined as diagnoses by healthcare professionals and treatments for depression. Eight hundred and nine participants were followed up from the baseline (2005) until wave 3 (2009) [median: 3.9 (IQR: 1.9–4.0) years; 109 incident cases). Cox proportional hazard models were used to estimate hazard ratios (95% CIs). All models were adjusted for demographic characteristics, lifestyle factors, and health history. Among 963 participants (mean age: 78.5; 5.8% females) in the cross-sectional analysis, compared with T1, higher vegetable intake was associated with fewer depressive symptoms (T2: β = 0.52; T3: β= −0.53; both p < 0.05), psychological distress (T2: β = −0.59; T3: β = −1.13; both p < 0.05), and anxiety symptoms (T3: β = −0.37; p = 0.03). Combined intake of vegetables and fruit was inversely associated with fewer psychological distress symptoms (T2: β = −0.55; p = 0.06; T3: β = −1.3; p < 0.05). In the highest tertile, dietary fibre was associated with fewer depressive symptoms (T3: β = −0.47; p = 0.04). In the longitudinal analysis, dietary fibre intake was associated with a 43–56% lower risk of incident dementia (T2 vs T1: adj.HR = 0.57; 95% CI: 0.31–1.03; T3 vs T1: adj.HR = 0.44; 95% CI: 0.19–1.01). Intakes of whole grains, fruit, nuts and legumes were not associated with the outcomes assessed. In a cohort of older Australians, dietary fibre intake appeared to be protective in reducing depressive symptoms cross-sectionally and the risk of incident dementia longitudinally. Additionally, vegetable consumption was associated with fewer symptoms related to depression, anxiety, and distress cross-sectionally.

Depression and dementia represent significant public health issues, affecting approximately 1 in 10 and 1 in 12 older Australians, respectively. While current pharmacological treatments are effective in relieving symptoms, they often entail undesirable adverse effects, including gastrointestinal issues and bradycardia(1,2). This highlights the need for primary preventative measures, including food- and nutrition-based approaches. Chronic brain inflammation is believed to interfere with the gut–brain axis(3). Consumption of fermented dairy products rich in beneficial gut microbes may attenuate this inflammation and offer protective health benefits. This study aimed to examine whether fermented dairy intake could mitigate the risk of incident depression and dementia. Utilising data from the Sydney Memory and Ageing Study I of 1037 participants 70–90 years, 816 participants (mean age: 76.7) were followed from 2005 until 2012 for incident depression, and 974 participants (mean age: 80.7) were followed up from 2005 until 2014 for incident dementia. Fermented dairy intake was assessed using the Dietary Questionnaire for Epidemiological Studies version 2 and categorised yoghurt and regular cheese into quartiles (Q) and low-fat cheese into consumers/non-consumers, with no consumption as the reference group. Depression diagnoses were assessed via self-reported physician-diagnosed history, medication use, service utilisation, and heavy alcohol use. Dementia diagnoses followed the criteria in the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders. Cox proportional hazards models examined the associations between fermented dairy intake and the risk of incident depression/dementia. Additionally, linear regression models were applied to assess for depressive symptoms score (measured by the Geriatric Depression Scale-15) and psychological distress score (measured by the Kessler Psychological Distress Scale-10). All models were adjusted for sociodemographic, lifestyle factors, and medical histories. Over a median follow-up of 3.9 and 5.8 years, 120 incident depression and 100 incident dementia cases occurred, respectively. Those who consumed high yoghurt (Q4: 145.8–437.4 g/day) and low-fat cheese (consumers: 0.4–103.1g/day) intakes were associated with a lower risk of incident depression, both compared to non-consumers (yoghurt: adj.HR: 0.38, 95% CI: 0.19–0.77; low-fat cheese: adj.HR: 0.50; 95% CI: 0.29–0.86). They were also associated with lower depressive symptom scores (yoghurt: adj.β = −0.46; 95% CI: −0.84, −0.07; low-fat cheese: adj.β = −0.42; 95% CI: −0.73, −0.11). However, those who consumed a higher intake of regular cheese (Q4: 14.7–86.1 g/day) had an elevated risk of incident depression (adj.HR: 1.88; 95% CI: 1.02, 3.47), and those in Q2 (0.1–7.2 g/day) had significantly higher depressive symptom scores (adj.β = 0.42; 95% CI: 0.05, 0.78). No significant findings were found for psychological distress scores or incident dementia. Our findings of a cohort of older Australians suggest that higher yoghurt and low-fat cheese intakes may reduce incident depression and depressive symptoms, while a higher intake of regular cheese may increase these risks.

In this article, we discuss the introduction and reception of the theology of natural and divine laws in late Ming China. Natural law and the twofold divine laws appear collectively as an object of discussion and exposition in a number of writings by Jesuit missionaries and Chinese Catholic converts of this time. We focus primarily on Michele Ruggieri’s Tianzhu shilu 天主實錄 (The True Record of the Lord of Heaven) and then consider additional texts by Yang Tingyun and Giulio Aleni, referring to other works in passing. While laying out in more detail than previous scholarship the scholastic basis of these discussions, we nonetheless emphasize that these texts do not reflect a fixed version of scholastic teaching but accommodate their discussions to Chinese cultural sensibilities and/or philosophical concepts. Our historical analysis serves as the basis for a comparative philosophical consideration of the relationship between the doctrine of natural law and the Chinese concept of liangzhi 良知 “innate moral knowledge”.

SHEA, in partnership with ASGE, APIC, AAMI, AORN, HSPA, IDSA, SGNA, and The Joint Commission, developed this multisociety infection prevention guidance document for individuals and organizations that engage in sterilization or high-level disinfection (HLD). This document follows the CDC Guideline for Disinfection and Sterilization in Healthcare Facilities. This guidance is based on a synthesis of published scientific evidence, theoretical rationale, current practices, practical considerations, writing group consensus, and consideration of potential harm when applicable. The supplementary material includes a summary of recommendations. The guidance provides an overview of the Spaulding Classification and considerations around manufacturers’ instructions for use (MIFUs). Its recommendations address: point-of-use treatment prior to sterilization or HLD, preparation of reusable medical devices at the location of processing, sterilization, and immediate use steam sterilization (IUSS), HLD of lumened and non-lumened devices, processing of reusable medical devices used with lubricating or defoaming agents, monitoring for effectiveness of processing, handling of devices after HLD, augments and alternatives to HLD, processing of investigational devices, tracking of reusable medical devices, and approaches to implementation.

With wide-field phased array feed technology, the Australian Square Kilometre Array Pathfinder (ASKAP) is ideally suited to search for seemingly rare radio transient sources that are difficult to discover previous-generation narrow-field telescopes. The Commensal Real-time ASKAP Fast Transient (CRAFT) Survey Science Project has developed instrumentation to continuously search for fast radio transients (duration $\lesssim$ 1 s) with ASKAP, with a particular focus on finding and localising fast radio bursts (FRBs). Since 2018, the CRAFT survey has been searching for FRBs and other fast transients by incoherently adding the intensities received by individual ASKAP antennas, and then correcting for the impact of frequency dispersion on these short-duration signals in the resultant incoherent sum (ICS) in real time. This low-latency detection enables the triggering of voltage buffers, which facilitates the localisation of the transient source and the study of spectro-polarimetric properties at high time resolution. Here we report the sample of 43 FRBs discovered in this CRAFT/ICS survey to date. This includes 22 FRBs that had not previously been reported: 16 FRBs localised by ASKAP to $\lesssim 1$ arcsec and 6 FRBs localised to $\sim 10$ arcmin. Of the new arcsecond-localised FRBs, we have identified and characterised host galaxies (and measured redshifts) for 11. The median of all 30 measured host redshifts from the survey to date is $z=0.23$. We summarise results from the searches, in particular those contributing to our understanding of the burst progenitors and emission mechanisms, and on the use of bursts as probes of intervening media. We conclude by foreshadowing future FRB surveys with ASKAP using a coherent detection system that is currently being commissioned. This will increase the burst detection rate by a factor of approximately ten and also the distance to which ASKAP can localise FRBs.

The interplay between selenoproteins, oxidative stress, and cell death pathways holds promise in unravelling novel therapeutic targets for Alzheimer’s disease (AD) in the future. Nonetheless, further comprehensive investigations are warranted to fully comprehend the precise contributions of selenoproteins in the aetiology and potential therapeutic strategies for Alzheimer’s disease. Previous work into gene expression networks in AD has included analysis of the entire transcriptome and, as of yet, has not yielded consistent insight into pathological pathways.1 Despite the comprehensive assessment of the transcriptome enabled by current technologies, one drawback of the whole transcriptome analysis is the risk of overlooking subtle yet significant variations in metabolic pathways.2 Thus, we aimed to assess gene expression of known selenoprotein and selenium-containing pathways in two different brain regions (dorsolateral prefrontal cortex (DPC) and posterior cingulate cortex (PCC)) across the AD spectrum. We used RNA sequencing data from The Rush University’s Religious Orders Study and Memory and Aging Project (ROSMAP) cohort available in the AD Knowledge Portal (https://www.synapse.org/).3 This study included data available for a total of 889 DPC and 647 PCC samples. Four pathological phenotypes were determined based on pathology (CERAD) and clinical (CDR) status: AD ([(+) pathology, (+) clinical], prodromal disease, corresponding to donors that have not received a clinical diagnosis despite the presence of pathological alterations ([(+) pathology, (−) clinical], controls ([(−) pathology, (−) clinical] and non-AD dementia [(+) pathology, (+) clinical]. This last group was excluded from the analysis as it is assumed they may have been misdiagnosed or presented with non-AD dementia. Six selenium or AD-related pathways were assessed, accounting for 421 unique genes. Group comparisons were performed using linear mixed modelling adjusted for age, sex, APOEe4 status and batch via DESeq2 package with Benjamini-Hochberg adjustment for multiple testing. A total of 18 genes significantly differed between AD and controls in both brain areas (same direction in both brain areas; P < 0.05), including eight selenoprotein genes or genes directly associated with selenoprotein synthesis. Fifteen of them were also different (same direction) in PCC (seven selenoprotein/selenoprotein synthesis genes), and four were different in DPC (four selenoprotein/selenoprotein synthesis genes) between AD and prodromal. Only three genes significantly differed between prodromal and control samples (DPC), including the selenoprotein DIO3 and the transcription factor SP3. Our findings indicate a progressive change in gene expression across the different stages of AD. These findings shed light on critical genes involved in selenoprotein synthesis that play a role in AD pathogenesis. Restricting the analysis to a subset of pathways enabled the detection of smaller alterations between groups, which is particularly appropriate in trace element homeostasis, where small alterations may have significant downstream effects.

Depression and eating disorder (ED) risk are heightened during adolescence(1) and both were exacerbated during COVID-19 lockdowns. This analysis reports changes in self-reported symptoms of depression and eating disorders throughout the Fast Track to Health trial. Fast Track to Health was a 52-week multi-site randomised-controlled trial, conducted 2018-2023, comparing intermittent (IER) and continuous energy restriction (CER) in adolescents with obesity and ≥1 associated comorbidity(2). The Centre for Epidemiologic Studies Depression Scale-revised 10-item version for adolescents (CESDR) was used to assess symptoms of depression (no symptoms, sub-threshold, or possible, probable, major depressive episode). Eating Disorder Examination Questionnaire (EDE-Q) was used to assess ED risk; defined as global score ≥2.7, ≥2 episodes of binge eating with/without loss of control, or ≥1 episode of purging within the last 28-days. The Binge Eating Scale (BES) assessed severity of binge eating (no binge eating, mild/moderate, severe). Adolescents were monitored for disordered eating during dietetic consults. Linear mixed models, retaining all data consistent with intention-to-treat analysis, were used to estimate the change in outcomes from baseline to week-52. Descriptive statistics were used to describe the number of participants meeting screening criteria at baseline and week-52. One hundred and forty one adolescents were enrolled and 97 completed the trial, with median (IQR) EDE-Q score 2.28 (1.43 to 3.14), CESDR 9.00 (4.0 to 14.5) and BES 11.0 (5.0 to 17.0) at baseline. EDE-Q (change in estimated marginal means [SE], IER −0.63 [0.18], CER −0.56 [0.17]) and CESDR (IER −2.70 [1.15], CER −3.87 [1.07]) scores reduced between baseline and week-52 in both groups (p<0.05) with no difference between groups. There was a between group difference (p = 0.019) in change in BES. The IER group had a reduction between baseline and week-52 (−3.72 [1.27]) and the CER group had no change. At baseline, 31 (22%) adolescents were classified as having a possible/probable/major depressive episode, 110 (78%) met ≥1 ED criteria and 28 (21%) as mild/moderate or severe binge eating, reducing to 8 (9%), 56 (61%) and 15 (16%) respectively at week-52. A small sub-group of adolescents required additional support for disordered eating. Overall, treatment-seeking adolescents with obesity have symptoms of depression and ED. Although symptoms reduce for most, some required additional support. Screening and monitoring for depression and ED are important to ensure early intervention.

Adolescent obesity requires effective and accessible intervention options and there is potential for intensive dietary interventions to be used as adjunctive therapy to behavioural weight management for some individuals(1). The aim of this study was to determine the effect of two novel diet therapies, delivered in the as part of an intensive behavioural weight management intervention, in adolescents with metabolic complications associated with obesity. The Fast Track to Health study (HREC/17/SCHN/164; ACTRN12617001630303) was a multi-site 52-week RCT, conducted 2018 – 2023, comparing a very-low-energy diet (800kcal/day) followed by i) an intermittent energy restricted (IER) diet; and ii) a continuous energy restricted diet (CER), for adolescents (13-17years) with ≥1 obesity associated complication. Interventions were delivered as part of an intensive behavioural weight management intervention by a multidisciplinary team2. Anthropometry, body composition and cardiometabolic health were assessed at baseline and week-52. The primary outcome was change in BMI z-score at week-52. Dyslipidaemia was defined as HDL <1.03mmol/L and/or triglycerides ≥1.7mmol/l, and elevated liver function tests (LFTs) as ALT and/or GGT ≥1.5 upper limit of 30U/L3. The difference in BMI z-score between groups at week-52 (±4) was assessed using a t-test. Mixed models was used to investigate changes over time. Descriptive statistics were used to describe participants above and below clinical cut-points at baseline and week-52. In total, 141 adolescents (70 female) were enrolled and 97 (48 female) completed the intervention. At week-52, BMI z-score reduced by −0.23 [95%CI −0.37 to −0.22], BMI expressed as a percentage of 95th percentile reduced by −8.86 [95%CI −12.46 to −7.47] and Fat Mass Index reduced by −1.49 [95%CI −2.36 to −1.08]. There was no significant difference for weight or cardiometabolic outcomes between diet groups. The occurrence of dyslipidaemia was unchanged between baseline and week-52 (n = 60 [43%] and n = 37 [43%] respectively) and a small improvement in the occurrence of impaired LFTs (n = 37 [27%] to n = 15 [17.2%] respectively). There were no differences in change of occurrence of dyslipidaemia or impaired LFTs between intervention groups. These findings suggest that both IER and CER, delivered as part of an intensive behavioural weight management program, are equally effective for improving weight and cardiometabolic outcomes for adolescents with obesity.

Background: SMA affects individuals with a broad age range and spectrum of disease severity. Risdiplam (EVRYSDI®) is a centrally and peripherally distributed, oral SMN2 pre-mRNA splicing modifier. Methods: SUNFISH is a multicenter, two-part, randomized, placebo-controlled, double-blind study in patients with Types 2/3 SMA. Part 1 assessed the safety, tolerability and pharmacokinetics/pharmacodynamics of different risdiplam dose levels in patients with Types 2/3 SMA. Part 2 assessed the efficacy and safety of the selected dose of risdiplam versus placebo in Type 2 and non-ambulant Type 3 SMA. In Part 2, participants were treated with risdiplam or placebo for 12 months, then received risdiplam in a blinded manner until month 24. At month 24, patients were offered the opportunity to enter the open-label extension phase. Results: Change from baseline in MFM32 total score (Part 2- primary endpoint) in patients treated with risdiplam versus placebo was met at month 12. These increases in motor function were sustained in the second and third year after risdiplam treatment. Here we present 4-year efficacy and safety data from SUNFISH. Conclusions: SUNFISH is ongoing and will provide further long-term efficacy and safety data of risdiplam in a broad population of individuals with SMA.

In Paper I, we presented an overview of the Southern-sky MWA Rapid Two-metre (SMART) survey, including the survey design and search pipeline. While the combination of MWA’s large field-of-view and the voltage capture system brings a survey speed of ${\sim} 450\, {\textrm{deg}}^{2}\,\textrm{h}^{-1}$, the progression of the survey relies on the availability of compact configuration of the Phase II array. Over the past few years, by taking advantage of multiple windows of opportunity when the compact configuration was available, we have advanced the survey to 75% of the planned sky coverage. To date, about 10% of the data collected thus far have been processed for a first-pass search, where 10 min of observation is processed for dispersion measures out to 250 ${\textrm{pc cm}}^{-3}$, to realise a shallow survey that is largely sensitive to long-period pulsars. The ongoing analysis has led to two new pulsar discoveries, as well as an independent discovery and a rediscovery of a previously incorrectly characterised pulsar, all from ${\sim} 3\% $ of the data for which candidate scrutiny is completed. In this sequel to Paper I, we describe the strategies for further detailed follow-up including improved sky localisation and convergence to timing solution, and illustrate them using example pulsar discoveries. The processing has also led to re-detection of 120 pulsars in the SMART observing band, bringing the total number of pulsars detected to date with the MWA to 180, and these are used to assess the search sensitivity of current processing pipelines. The planned second-pass (deep survey) processing is expected to yield a three-fold increase in sensitivity for long-period pulsars, and a substantial improvement to millisecond pulsars by adopting optimal de-dispersion plans. The SMART survey will complement the highly successful Parkes High Time Resolution Universe survey at 1.2–1.5 GHz, and inform future large survey efforts such as those planned with the low-frequency Square Kilometre Array (SKA-Low).

We present an overview of the Southern-sky MWA Rapid Two-metre (SMART) pulsar survey that exploits the Murchison Widefield Array’s large field of view and voltage-capture system to survey the sky south of 30$^{\circ}$ in declination for pulsars and fast transients in the 140–170 MHz band. The survey is enabled by the advent of the Phase II MWA’s compact configuration, which offers an enormous efficiency in beam-forming and processing costs, thereby making an all-sky survey of this magnitude tractable with the MWA. Even with the long dwell times employed for the survey (4800 s), data collection can be completed in $<$100 h of telescope time, while still retaining the ability to reach a limiting sensitivity of $\sim$2–3 mJy (at 150 MHz, near zenith), which is effectively 3–5 times deeper than the previous-generation low-frequency southern-sky pulsar survey, completed in the 1990s. Each observation is processed to generate $\sim$5000–8000 tied-array beams that tessellate the full $\sim 610\, {\textrm{deg}^{2}}$ field of view (at 155 MHz), which are then processed to search for pulsars. The voltage-capture recording of the survey also allows a multitude of post hoc processing options including the reprocessing of data for higher time resolution and even exploring image-based techniques for pulsar candidate identification. Due to the substantial computational cost in pulsar searches at low frequencies, the survey data processing is undertaken in multiple passes: in the first pass, a shallow survey is performed, where 10 min of each observation is processed, reaching about one-third of the full-search sensitivity. Here we present the system overview including details of ongoing processing and initial results. Further details including first pulsar discoveries and a census of low-frequency detections are presented in a companion paper. Future plans include deeper searches to reach the full sensitivity and acceleration searches to target binary and millisecond pulsars. Our simulation analysis forecasts $\sim$300 new pulsars upon the completion of full processing. The SMART survey will also generate a complete digital record of the low-frequency sky, which will serve as a valuable reference for future pulsar searches planned with the low-frequency Square Kilometre Array.

Background: Phase 3 COMET trial (NCT02782741) compares avalglucosidase alfa (n=51) with alglucosidase alfa (n=49) in treatment-naïve LOPD. Methods: Primary objective: determine avalglucosidase alfa effect on respiratory muscle function. Secondary/other objectives include: avalglucosidase alfa effect on functional endurance, inspiratory/expiratory muscle strength, lower/upper extremity muscle strength, motor function, health-related quality of life, safety. Results: At Week 49, change (LSmean±SE) from baseline in upright forced vital capacity %predicted was greater with avalglucosidase alfa (2.89%±0.88%) versus alglucosidase alfa (0.46%±0.93%)(absolute difference+2.43%). The primary objective, achieving statistical non-inferiority (p=0.0074), was met. Superiority testing was borderline significant (p=0.0626). Week 49 change from baseline in 6-minute walk test was 30.01-meters greater for avalglucosidase alfa (32.21±9.93m) versus alglucosidase alfa (2.19±10.40m). Positive results for avalglucosidase alfa were seen for all secondary/other efficacy endpoints. Treatment-emergent adverse events (AEs) occurred in 86.3% of avalglucosidase alfa-treated and 91.8% of alglucosidase alfa-treated participants. Five participants withdrew, 4 for AEs, all on alglucosidase alfa. Serious AEs occurred in 8 avalglucosidase alfa-treated and 12 alglucosidase alfa-treated participants. IgG antidrug antibody responses were similar in both. High titers and neutralizing antibodies were more common for alglucosidase alfa. Conclusions: Results demonstrate improvements in clinically meaningful outcome measures and a more favorable safety profile with avalglucosidase alfa versus alglucosidase alfa. Funding: Sanofi Genzyme

The Variables and Slow Transients Survey (VAST) on the Australian Square Kilometre Array Pathfinder (ASKAP) is designed to detect highly variable and transient radio sources on timescales from 5 s to $\sim\!5$ yr. In this paper, we present the survey description, observation strategy and initial results from the VAST Phase I Pilot Survey. This pilot survey consists of $\sim\!162$ h of observations conducted at a central frequency of 888 MHz between 2019 August and 2020 August, with a typical rms sensitivity of $0.24\ \mathrm{mJy\ beam}^{-1}$ and angular resolution of $12-20$ arcseconds. There are 113 fields, each of which was observed for 12 min integration time, with between 5 and 13 repeats, with cadences between 1 day and 8 months. The total area of the pilot survey footprint is 5 131 square degrees, covering six distinct regions of the sky. An initial search of two of these regions, totalling 1 646 square degrees, revealed 28 highly variable and/or transient sources. Seven of these are known pulsars, including the millisecond pulsar J2039–5617. Another seven are stars, four of which have no previously reported radio detection (SCR J0533–4257, LEHPM 2-783, UCAC3 89–412162 and 2MASS J22414436–6119311). Of the remaining 14 sources, two are active galactic nuclei, six are associated with galaxies and the other six have no multi-wavelength counterparts and are yet to be identified.

Several decades of research have addressed the role of information and communication technologies (ICTs) in industrial-organizational (I-O) psychology. However, segmented research streams with myriad terminologies run the risk of construct proliferation and lack an integrated theoretical justification of the contributions of ICT concepts. Therefore, by identifying important trends and reflecting on key constructs, findings, and theories, our review seeks to determine whether a compelling case can be made for the uniqueness of ICT-related concepts in studying employee and performance in I-O psychology. Two major themes emerge from our review of the ICT literature: (a) a technology behavior perspective and (b) a technology experience perspective. The technology behavior perspective with three subcategories (the “where” of work design, the “when” of work extension, and the “what” of work inattention) explores how individual technology use can be informative for predicting employee well-being and performance. The technology experience perspective theme with two subcategories (the “how” of ICT appraisals and “why” of motives) emphasizes unique psychological (as opposed to behavioral) experiences arising from the technological work context. Based on this review, we outline key challenges of current ICT research perspectives and opportunities for further enhancing our understanding of technological implications for individual workers and organizations.

The recent increase in well-localised fast radio bursts (FRBs) has facilitated in-depth studies of global FRB host properties, the source circumburst medium, and the potential impacts of these environments on the burst properties. The Australian Square Kilometre Array Pathfinder (ASKAP) has localised 11 FRBs with sub-arcsecond to arcsecond precision, leading to sub-galaxy localisation regions in some cases and those covering much of the host galaxy in others. The method used to astrometrically register the FRB image frame for ASKAP, in order to align it with images taken at other wavelengths, is currently limited by the brightness of continuum sources detected in the short-duration (‘snapshot’) voltage data captured by the Commensal Real-Time ASKAP Fast Transients (CRAFT) software correlator, which are used to correct for any frame offsets due to imperfect calibration solutions and estimate the accuracy of any required correction. In this paper, we use dedicated observations of bright, compact radio sources in the low- and mid-frequency bands observable by ASKAP to investigate the typical astrometric accuracy of the positions obtained using this so-called ‘snapshot’ technique. Having captured these data with both the CRAFT software and ASKAP hardware correlators, we also compare the offset distributions obtained from both data products to estimate a typical offset between the image frames resulting from the differing processing paths, laying the groundwork for future use of the longer duration, higher signal-to-noise ratio (S/N) data recorded by the hardware correlator. We find typical offsets between the two frames of ${\sim}0.6$ and ${\sim}0.3$ arcsec in the low- and mid-band data, respectively, for both RA and Dec. We also find reasonable agreement between our offset distributions and those of the published FRBs. We detect only a weak dependence in positional offset on the relative separation in time and elevation between target and calibrator scans, with the trends being more pronounced in the low-band data and in Dec. Conversely, the offsets show a clear dependence on frequency in the low band, which we compare to the frequency-dependent Dec. offsets found in FRB 200430. In addition, we present a refined methodology for estimating the overall astrometric accuracy of CRAFT FRBs.